PNC Financial Services Group’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-319
Closed -$1.18K – 5471
2026
Q2
$1.18K Hold
319
– – ﹤0.01% 4811
2026
Q1
$1.11K Hold
319
– – ﹤0.01% 4737
2025
Q4
$1.11K Hold
319
– – ﹤0.01% 4670
2025
Q3
$1.77K Hold
319
– – ﹤0.01% 4536
2025
Q2
$788 Sell
319
-5
-2% -$8 ﹤0.01% 4599
2025
Q1
$645 Buy
324
+178
+122% +$454 ﹤0.01% 4588
2024
Q4
$426 Buy
146
+118
+421% +$414 ﹤0.01% 4553
2024
Q3
$108 Sell
28
-86
-75% -$398 ﹤0.01% 4717
2024
Q2
$586 Buy
+114
New +$691 ﹤0.01% 4509

Other funds holding PRME

PNC Financial Services Group's PRME Position: Q3 2026 in Review

PNC Financial Services Group sold out of Prime Medicine (PRME) in Q3 2026, closing a stake of 319 shares — an estimated $1.18K sold.

PNC Financial Services Group first reported a position in PRME in Q2 2024 and held it in 9 quarters. The position peaked at $1.77K in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • PNC Financial Services Group reported no remaining Prime Medicine position as of Q3 2026 after selling out during the quarter.
  • PNC Financial Services Group sold 319 Prime Medicine shares in Q3 2026, an estimated $1.18K.
  • PNC Financial Services Group first reported a position in Prime Medicine in Q2 2024 and held it in 9 quarters.
  • PNC Financial Services Group's Prime Medicine position peaked at $1.77K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.